Hyperphosphatemia
Conditions
Interventions
Single oral administration of TS-172 20mg during fasting
Sponsors
Seiji Mita
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Japanese male and female patients whose age is >=18 and 1. Japanese male and female patients whose age is >=18 and =18.5 and <35.0 at the screening test Other protocol defined inclusion criteria could apply.
Exclusion criteria
Exclusion criteria: 1. Patients with medical history of liver resection or liver transplantation 2. Patients with grade II or higher hepatic encephalopathy 3. Patients whose eGFR is 1. Subjects with current condition or medical history of diseases that are ineligible for participation in the study 2. Subjects whose eGFR is <60 mL/min/1.73 m2 at screening test Other protocol defined exclusion criteria could apply.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma concentrations of unchanged form and metabolites | — |
Contacts
Public ContactDevelopment Headquarters Development Management
Taisho Pharmaceutical Co., LTD.
Outcome results
None listed